Dimitra P Anastasiadou
Overview
Explore the profile of Dimitra P Anastasiadou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anastasiadou D, Couturier N, Goel S, Argyris D, Vodopyanov S, Rivera-Sanchez L, et al.
bioRxiv
. 2024 Oct;
PMID: 39464015
Although the CXCL12/CXCR4 pathway has been prior investigated for its prometastatic and immuno- suppressive roles in the tumor microenvironment, evidence on the spatiotemporal regulation of these hallmarks has been lacking....
2.
Baugh A, Gonzalez E, Narumi V, Kreger J, Liu Y, Rafie C, et al.
Clin Exp Metastasis
. 2024 May;
41(5):733-746.
PMID: 38717519
Metastatic disease results from the dissemination of tumor cells beyond their organ of origin to grow in distant organs and is the primary cause of death in patients with advanced...
3.
Baugh A, Gonzalez E, Narumi V, Kreger J, Liu Y, Rafie C, et al.
bioRxiv
. 2024 Feb;
PMID: 38352476
Preclinical murine models in which primary tumors spontaneously metastasize to distant organs are valuable tools to study metastatic progression and novel cancer treatment combinations. Here, we characterize a novel syngeneic...
4.
Anastasiadou D, Quesnel A, Duran C, Filippou P, Karagiannis G
Cytokine Growth Factor Rev
. 2023 Nov;
75:12-30.
PMID: 37949685
The chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF1), has emerged as a pivotal regulator in the intricate molecular networks driving cancer progression. As an influential factor in...
5.
Lagou M, Anastasiadou D, Karagiannis G
Front Immunol
. 2022 Jul;
13:933547.
PMID: 35844592
Epidemiologic data suggest that cancer survivors tend to develop a protuberant number of adverse late effects, including second primary malignancies (SPM), as a result of cytotoxic chemotherapy. Besides the genotoxic...